Conditions: Carcinoma, Non-Small-Cell Lung ErbB Receptors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Afatinib
Intervention descriptions: intervention 1: None

Protocol document: